Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital’s Perspective

BACKGROUND: Tisagenlecleucel was approved for the treatment of pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) based on the pivotal ELIANA trial. OBJECTIVE: To comprehensively evaluate the total costs associated with tisagenlecleucel treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hongbo, Hao, Yanni, Qi, Cynthia Z., Chai, Xinglei, Wu, Eric Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391202/
https://www.ncbi.nlm.nih.gov/pubmed/32525730
http://dx.doi.org/10.18553/jmcp.2020.20052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391202/
https://www.ncbi.nlm.nih.gov/pubmed/32525730
http://dx.doi.org/10.18553/jmcp.2020.20052

Ejemplares similares